Genprex, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
GNPX$2.06-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2025 | 2024 | |
| Operating expenses: | ||
| Depreciation | $— | $6,693 |
| Research and development | 9,428,720 | 10,535,446 |
| General and administrative | 6,086,899 | 10,632,028 |
| Total operating expenses | 15,515,619 | 21,174,167 |
| Operating loss | (15,515,619) | (21,174,167) |
| Other income | 26,900 | 63,574 |
| Other financing costs | (739,935) | — |
| Realized and unrealized loss | (299) | (570) |
| Net loss | (16,228,953) | (21,111,163) |
| Deemed dividend related to warrant modification | — | (277,119) |
| Net loss attributable to common stockholders | $(16,228,953) | $(21,388,282) |
| Net loss per share applicable to common stockholders — basic and diluted | $(17.40) | $(266.89) |
| Weighted average number of common shares — basic and diluted | 932,730 | 80,139 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.